Ontology highlight
ABSTRACT:
SUBMITTER: Schettini F
PROVIDER: S-EPMC10757006 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
Schettini Francesco F Giudici Fabiola F Generali Daniele D
Heliyon 20231206 1
In the last couple of decades substantial therapeutic improvements deeply influenced the treatment of HER2-positive metastatic breast cancer. The most impactful advancements were obtained especially in the first-line setting, with the trastuzumab/pertuzumab anti-HER2 double blockade, and in the second line, with the advent of the potent antibody-drug conjugate trastuzumab deruxtecan. Nevertheless, a careful observation of the patterns of early-progression and long-term effects on overall surviva ...[more]